Clinical trials: Chorea, Huntington
Huntington Disease
Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease
This study will investigate if a new experimental drug to treat Huntington's Disease gets into the brain. If it does get into the brain the study will explore the relationship between the amount of drug in the brain and the…
- Trial name
- NCT01602900
- Testing
- GSK356278, Rolipram
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Huntington Disease
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
- Trial name
- NCT05358821
- Testing
- SAGE-718
- Where
- 14 sites in United States, Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Huntington Disease
Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease
The objective of the study is to validate the use of wearable sensors and digital health technologies for monitoring disease activity in Huntington's Disease (HD).
- Trial name
- BioDigit HD-02 (NCT07315984)
- Where
- 2 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- BioSensics
Huntington's Disease, Tourette Syndrome
Brain Stimulation in Movement Disorders
Brain stimulation in movement disorders This trial will explore the effects of very gentle electrical stimulation of the brain in patients with movement disorders.
- Trial name
- NCT02216474
- Testing
- Transcranial direct current stimulation
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Birmingham and Solihull Mental Health NHS Foundation Trust
Huntington Disease, Huntington's Disease
REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN)
This is a multi-centre, multi-national, prospective, observational study of Huntington's disease (HD) with a control group of volunteers to: obtain natural history data on many HD mutation carriers and individuals who are part of…
- Trial name
- REGISTRY (NCT01590589)
- Where
- 140 sites in Austria, Belgium and 15 more
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- European Huntington's Disease Network
Huntington Disease
Prospective Huntington At Risk Observational Study
The purpose of this study is to define the natural history and experiences of people who are at risk for developing Huntington's disease but who do not know their genetic status.
- Trial name
- PHAROS (NCT00052143)
- Where
- 42 sites in United States, Canada
- Volunteers
- 1,001 people, healthy volunteers welcome
- Sponsor
- Huntington Study Group
Alzheimer Disease, Huntington Disease
Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects
This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and…
- Trial name
- NCT00831506
- Testing
- digoxin, dimebon
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer's Disease, Huntington's Disease
A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects
This study is to characterize the pharmacokinetics of single and multiple oral doses of Dimebon in Japanese healthy subjects. This study is also to evaluate the safety and tolerability of single and multiple oral doses of Dimebon…
- Trial name
- NCT00825084
- Testing
- Dimebon
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Pfizer
Huntington Disease
Study of Biomarkers That Predict the Evolution of Huntington's Disease
Huntington's disease (HD) is a rare, autosomal dominant, progressive neurodegenerative disorder typically becoming noticeable in middle age.
- Trial name
- BIOHD (NCT01412125)
- Testing
- Huntington patient evaluation, Healthy subject evaluation
- Where
- France
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Huntington Disease
A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278
The study drug, GSK356278, is a possible new medicine for the treatment of Huntington's disease. Huntington's disease, which is often called HD, is caused by a faulty gene that is passed down through families.
- Trial name
- NCT01573819
- Testing
- GSK356278
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Huntington Disease
Dance and Huntington Disease
In this project investigators will evaluate the benefits of contemporary dance training using a comprehensive test battery combining standard neuropsychological batteries, psychological questionnaires on emotion, empathy and…
- Trial name
- NCT01842919
- Testing
- Kinesthetics tests, Psychological questionnaires, structural Magnetic ResonanceImaging (MRI)
- Where
- France
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Huntington Disease, Tardive Dyskinesia
Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets
This is a A single-center, randomized, open-label, two-dose, two-period, crossover trial was conducted to evaluate the effect of food on the Pharmacokinetic characteristics and safety of oral administration of LPM3770164…
- Trial name
- NCT06474650
- Testing
- LPM3770164 sustained release tablet
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Huntington Disease, Autobiographical Memory
Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease
Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by progressively worsening motor, cognitive, psychiatric, and behavioral deficits.
- Trial name
- MAMOC-MH (NCT07409597)
- Testing
- neuropsychological tests, Eye tracker use
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Huntington Disease, Alzheimer Disease
Striatum and Hippocampus on Different Time Scales
Time processing is fundamental to survival and goal reaching in humans. Different time scales (seconds, minutes, and beyond) are processed through specific cognitive processes involving different neural representations.
- Trial name
- e-Time (NCT05943054)
- Testing
- Temporal perception tasks
- Where
- France
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Huntington Disease, Healthy
Digital Measures for Clinical Trial Endpoints in Huntington's Disease
MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons.
- Trial name
- MEND-HD (NCT07010705)
- Testing
- ActiGraph LEAP, Axivity AX6
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Huntington Disease
iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626
This is a FIH (first-in-human) adaptive PET (Positron Emission Tomography) imaging study to explore the binding and kinetic properties of two potential mutant huntingtin (mHTT) radioligands; [¹¹C]CHDI-00485180-R and…
- Trial name
- NCT03810898
- Testing
- Radioligand [¹¹C]CHDI-00485180-R, Radioligand [¹¹C]CHDI-00485626
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CHDI Foundation, Inc.
Huntington Disease
Huntington's Disease Biobank: Advancing Remote Monitoring and Deep Phenotyping
This observational study aims to identify novel biomarkers of disease onset and progression in Huntington's disease by integrating remote monitoring with fluid biomarkers.
- Trial name
- NCT06941662
- Testing
- computer vision, remote monitoring, blood, urine, wrist bands, mobile-app
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Stanford University
Huntington Disease
Benchmarking Integrated Care for People Living With Huntington's Disease in England
The survey and full study information can be accessed here: https://southampton.qualtrics.com/jfe/form/SV_8iEedDJZy4xaiI6 The goal of this anonymous survey is to benchmark integrated care from the perspective of service users in…
- Trial name
- Integrate-HD (NCT05828992)
- Testing
- No intervention administered
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Southampton
Huntington Disease
Move to Improve: Telehealth Exercise to Music for HD
The purpose of this study is to determine if a movement to music exercise program delivered via telehealth is feasible and safe for individuals with neurodegenerative disease and their caregivers (Aim 1).
- Trial name
- MtI (NCT05270681)
- Testing
- Movement to Music
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Huntington Disease, White Matter Alterations
Decoding Presymptomatic White Matter Changes in Huntington Disease
WIN-HD is a monocentric longitudinal study comparing premanifest Huntingtin (HTT) mutation carriers and non HTT mutation carriers to determine that white-matter atrophy occurs far earlier than clinical onset in HD using…
- Trial name
- Win-HD (NCT03193099)
- Testing
- Brain imaging, Neurological assessments, Psychological assessments
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France